few year grow interest geriatr oncolog mainli becaus evid advanc ag greatest risk factor develop cancer elderli popul rapidli expand will number cancer patient forecast necessit develop specif strategi prevent cure cancer elderli result ever-increas need oncologist geriatrician research work close togeth increas incid cancer elderli peopl relat ag-associ chang occur immun system so-call immunosenesc phenomenon best characteris remodel immun system appear earli progress person's life mainli involv decreas cellular function review aim provid rational develop specif immunotherapeut immunoprevent regimen elderli includ discuss influenc immunosenesc growth tumour effect immunogen therapi cancer vaccin brief analysi ag-relat alter cell popul involv antitumour immun
cancer result genet alter intracellular signal pathwai normal orchestr execut development program organism respons extrins factor mutat upstream activ compon cytoplasm ra-raf mek-erk cascad frequent occur tumor vitro vivo studi shown isol activ pathwai both necessari suffici transform year two group relat kinas join rank mitogen-activ protein kinas stress-activ protein kinas/jun n-termin kinas p38 activ occur cellular respons unphysiolog stimuli downstream cytokin pathogen receptor observ tumor articl will review role stress kinas cancer discuss mechan through regul transform process
examin express function osteopontin opn oral cancer cell line us antisens oligonucleotid quantit real-time rt-pcr show express bsc-of cell significantli higher 10-fold cell as-studi show foci as-treat bsc-of cell possess thin process radiat morpholog bsc-of cell show round foci cell growth as-group lower &lt control invas abil as-group becam significantli lower p&lt 0.01 result suggest bsc-of cell us over-express opn opn contribut morpholog growth invas
receptor tyrosin kinas egfr famili transmit extracellular signal control divers cellular function prolifer differenti surviv signal function member famili her3 believ impair due deviat kinas consensu motif here address function role signal mechan her3 her3 preferenti form heterodim her2 induc most potent mitogen signal among egfr famili member data show glioma-deriv cell line cytoplasm tyrosin kinas pyk2 constitut associ her3 stimul heregulin result pyk2 tyrosin phosphoryl her3 her2 mediat phosphoryl c-termin region pyk2 promot mitogen respons through activ mapk pathwai central role pyk2 signal downstream her3 substanti demonstr express domin-neg pyk2-km construct abrog heregulin-induc mapk activ inhibit invas potenti glioma cell result suggest novel heregulin/her3-stimul signal pathwai glioblastoma-deriv cell line involv phosphoryl pyk2 mediat invas glioma cell
sentinel lymph node sln regard first tumor-drain lymph node initi site activ tumor antigen clarifi immunolog function sln total tumor-free region lymph node sln non-sln obtain patient oral caviti cancer infiltr both dc cell determin immunohistochemistri s-100+ cd1a+ dc infiltr significantli sln compar non-sln analysi pn0 pn+ patient show marker pn0 patient s-100+ pn+ patient significantli abund sln moreov infiltr cd83+ dc pn+ patient pn0 patient result suggest signific immun respons cancer occur sln non-sln howev progress diseas includ nodal diseas caus system immunosuppress
purpos review purpos paper review most recent medic literatur pertain neuroblastoma clinic progress continu made refin radiograph stage risk stratif-base treatment recent find meanwhil experiment effort focu continu search biolog prognost marker develop novel therapi includ second-gener retinoid tumor vaccin mode drug deliveri improv safeti efficaci summari review recent neuroblastoma literatur demonstr continu progress abil understand treat enigmat tumor
background number american student pursu advanc scienc degre continu wane summer research experi program ideal mechan introduc high school colleg student scientif lifestyl method follow-up particip 1995-2003 conduct gaug student percept program measur outcom result data present respons 287 particip program success recruit femal underrepres student high percentag traine report pursu advanc scientif studi high school colleg student conclus summer research experienti program success initi maintain student's interest scienc career
background train medic student tobacco prevent treatment skill critic compet physician prepar address grave level morbid mortal associ tobacco us tobacco prevent cessat educ medic school pace nation cancer institut fund project launch assess improv curriculum content teach medic school method 2003 survei complet faculti administr survei divid four main section tobacco content skill curricular evalu faculti percept barrier promot educ vision result thirti-six percent medic school cours tobacco-relat content five school provid total hour teach school provid 10-13 hour school provid hour teach school fewer hour devot tobacco teach clerkship 1st-year cours school note tobacco content obstetr/gynecolog clerkship school provid teach pediatr set rang 5-201 minut conclus comparison earlier studi appear tobacco content integr medic school cours improv necessari howev particularli tobacco us prevent institut need examin role faculti priorit tobacco inform promot cultur build compet tobacco control treatment
present review first year hospic geriatr institut pio albergo trivulzio milan itali's first public hospic admiss termin ill patient 1200 patient admit nine-bed hospic octob 1991 decemb 2001 most refer home palli care unit oper milan hospic patient elderli year ag median year admiss hospic patient's death patient brief time week averag outset striven focu attent daili applic programm care inspir philosophi practic palli medicin i.e holist approach attent devot qualiti life multidimension assess servic multiprofession team provid alongsid medic nurs assist psychosoci spiritu support bereav support continu educ health worker systemat us clinic audit tool specif design palli care two kei element judgement prove most fruit reach object describ year pio albergo trivulzio hospic made signific contribut defin concret italian model appli care termin ill inpati
fatigu frequent problem surgic treatment solid tumour aerob exercis psychosoci intervent shown reduc sever symptom cancer patient compar effect two therapi fatigu randomis control studi seventi-two patient underw surgeri lung gastrointestin tumour assign aerob exercis group stationari bike min five time weekli progress relax train group min three time per week both intervent carri week studi evalu physic cognit emot statu somat complaint european organ research treatment cancer qualiti life questionnair core modul eortc-qlq-30 questionnair maxim physic perform ergometr stress test physic perform train group improv significantli programm 9.4+/-20 watt 0.01 remain unchang relax group 1.5+/-14.8 watt 0.37 fatigu global health score improv both group intervent fatigu train group relax group global health both group &lt 0.01 howev signific differ chang score both group 0.67 conclud structur aerob train programm improv physic perform patient recov surgeri solid tumour howev exercis better progress relax train treatment fatigu set
zinc uptak critic cell prolifer basi evid brain tumor posit-imag 65zn cellular zinc uptak studi under growth arrest apoptosi understand relationship cellular viabil zinc uptak nih3t3 cell cultur albumin-coat dish under presenc serum viabil cell detach extracellular matrix determin fluorescein diacet almost same control cell cultur untreat dish both uptak 14c-thymidin 65zn cell significantli suppress detach extracellular matrix suggest cellular zinc uptak suppress growth arrest apoptosi induc cell detach extracellular matrix under serum-free condit 65zn uptak cell led apoptosi significantli higher control cell 65zn uptak glioma cell irradi gamma-rai higher control unirradi glioma cell present studi demonstr zinc uptak involv process cell prolifer process apoptosi
chk1 checkpoint kinas serin-threonin kinas critic g2/m arrest respons dna damag chk1 phosphoryl cdc25c serin-216 major regulatori site respons dna damag furthermor chk1 phosphoryl cdc25a serin 123 acceler degrad through ubiquitin-proteasom pathwai arrest cell late g2-phase dna damag present studi demonstr chk1 phosphoryl pro-apoptot protein bad bcl-2/bcl-xl-antagonist caus cell death vitro vitro phosphoryl analysi variou mous bad peptid reveal two phosphoryl site chk1 serin-155 serin-170 wild-type mutant bad s155a construct transfect 293t cell associ bad chk1 observ co-immunoprecipit addit increas phosphoryl serin-155 dna damag adriamycin treatment result suggest chk1 associ bad phosphoryl bad protein serin-155 taken togeth result suggest chk1 inactiv bad associ phosphoryl residu critic bad function respons dna damag
paneth cell adenoma ileum recent found 47-year-old male famili adenomat polyposi fap patient year previous subject total proctocolectomi surgeri endoscop biopsi obtain duodenum biopsi four instanc ileal pouch biopsi three biopsi taken 1988 2003 hematoxylin eosin h&amp section biopsi review on biopsi ileal pouch tubular adenoma carri dysplast paneth cell found paneth cell easili singl h&amp section observ fluoresc microscop us convent transmit light lysozym immunostain despit wide distribut paneth cell mucosa intestin metaplasia e.g barrett's esophagu gastric intestin metaplasia normal small intestin larg intestin chronic inflammatori diseas few paneth cell neoplasia report tract caus appar natur resist special cell provid anti-microbi growth factor undergo neoplast transform deserv investig review literatur indic first report case paneth cell adenoma small intestin
preclin model antiepilept drug valproic acid induc differenti neoplast cell repres evolv anticanc approach take account malign cell resembl immatur progenitor cell capabl termin differenti author report child suffer relaps supratentori primit neuroectoderm tumor receiv valproic acid epilepsi treatment month befor relaps contrast initi tumor relaps tumor show glial differenti low prolifer index first report relaps supratentori primit neuroectoderm tumor show histolog confirm sign tumor cell differenti induct
purpos research evalu role echo colour/power doppler magnet reson imag mri diagnosi expans parotid lesion establish criteria differenti diagnosi benign malign form forti nine patient male femal ag year expans patholog parotid gland enrol studi februari 1999 through august 2004 patient carefulli assess emploi both ultrasonographi integr color/power doppler mri eventu patient receiv echo-guid needl-biopsi surgic excis parotid lesion preliminari ultrasound assess site size echoic appear margin lesion order assess blood suppli mean colour/power doppler divid patient four group mri diagnost criteria includ site size intens signal behaviour lesion i.v contrast relationship facial nerv retromandibular vein detect margin proxim adjac structur basi result author conclud both echo colour/power doppler mri plai import role diagnosi surgic plan parotid gland lesion
recent paper zong describ alkyl agent kill cell process term program necrosi induc excess activ parp result degrad cytosol nad inhibit glycolysi argu obviou whether chemotherapi patient induc suffici nad loss affect glycolysi program natur necrosi requir evid mechan make cancer cell hypersensit dna damag high rate aerob glycolysi
object data surveil epidemiolog result tumor registri cover u.s popul us provid nation estim cancer incid surviv cancer mortal data u.s seer compar assess represent seer u.s method comparison seer cancer mortal made lead caus cancer death cancer site-specif comparison made race sex addit tobacco-relat cancer consid analys perform year seer registri includ seer program poisson regress us estim site-specif cancer mortal rate ratio u.s seer result cancer site-specif mortal rate deriv seer data tend under-repres u.s cancer mortal experi white male femal black male under-represent observ across major seer registri highest amount under represent utah mexico under-represent seer data compar data notic greater among tobacco-relat cancer particularli utah mexico conclus certain cancer site particularli tobacco-relat cancer seer coverag popul repres u.s popul
nf-kappab famili transcript factor well-known regul immun inflammatori respons recent identifi molecular link chronic inflamm cancer us distinct model inflamm-associ cancer three recent report show import nf-kappa promot cancer progress inflamm greten cell 2004 118 285-96 luo cancer cell 2004 297-305 pikarski natur 2004 431 461-6 result studi suggest nf-kappa exert oncogen effect both tumor cell tumor microenviron promot surviv premalign epitheli cell stimul releas pro-inflammatori mediat activ macrophag promot tumor growth
acut graft-versu-host diseas agvhd continu problem allogen transplant recent advanc understand induct propag gvhd lead transplant strategi treatment agvhd overview cover basic pathophysiolog prophylaxi treatment disord
purpos review mathemat model tumorigenesi fast-grow area research review describ recent juli 2003 advanc area discuss possibl implic field cancer biologi gener recent find broadli speak three major area theori contribut most cancer research model context epidemiolog statist data mechanist model avascular vascular tumor growth model cancer initi progress somat evolut first area us model fit exist data second approach take advantag method physic engin describ tumor growth third method look cancer progress local darwinian evolut summari articl describ interest idea forward year suggest make model effort relev better dialogu develop theorist experiment biologist author believ possibl
purpos aim work studi us techniqu extirp malign tumor maxillari sinu includ exposur adequ tumor resect preserv much possibl function tissu integr approach will evalu includ advantag disadvantag regard physiolog function aesthet outcom complic relat procedur method fourteen patient underw midfaci deglov techniqu excis malign maxillari sinu tumor period 1999 2003 nation cancer institut cairo univers procedur us basic incis sublabi incis bilater intercartilagin incis septocolumellar-complet transfixion incis bilater pyriform apertur incis extend vestibul immedi reconstruct palat defect done case prosthet obtur result patient successfulli underw plan procedur through midfaci deglov approach treatment malign lesion maxilla signific complic fifti patient immedi postop face edema resolv week oral infect occur patient sequela nasal crust infraorbit hypoesthesia both resolv month conclus midfaci deglov approach offer good exposur mid third face excel cosmet result approach combin down fractur maxilla access expos resect sinonas malign midfaci deglov techniqu consid valuabl procedur low mortal excel cosmet outcom
